Skip to main content

CD123-CAR T

CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

  • RegistryNCT04318678
  • PhasePhase 1
  • StatusRecruiting
  • ConditionAML/MDS
  • SponsorSt. Jude Children's Research Hospital
How CD123-CAR T worksNCT043186781 min

What the film says

Read the transcript

Acute myeloid leukemia in children is harder to treat than the common childhood leukemia; when it returns after transplant, options are few.

The idea: a CAR T cell for AML, built at the hospital that treats these children most.

The cells target CD123, a receptor found on AML cells, on the leukemia stem cells that seed relapse, and on several rarer leukemias. T cells from the child, or their prior transplant donor, are fitted with the receptor and infused once after chemotherapy clears space.

The first question is safety, since CD123 also sits on some normal blood-forming cells.

CATCHAML runs at St. Jude in Memphis, for patients up to twenty-one, led by Swati Naik and Paulina Velasquez. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT04318678

    Pediatric AML harder to treat than ALL; relapse after transplant; CD123 on AML/MDS, B-ALL, T-ALL, BPDCN; CD123 on leukemia stem cells; Autologous or prior-transplant-donor-derived cells; single infusion after Flu/Cy (+2 more lines)

The drug

What is being tested.

To treat relapsed/refractory CD123+ AML/MDS, B-ALL, T-ALL or BPDCN patient population that needs new cancer-directed therapies.

Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.

This study will evaluate the safety and maximum tolerated dose of CD123-CAR T cells. This study contains 2 phases. The first part is the called the "Collection and Manufacturing Phase" and the second is the "Treatment Phase". The Collection and Manufacturing Phase refers to your blood cells being collected and possibly frozen, via a process called apheresis. These cells will then be changed to improve their ability to recognize and kill cancer cells.

The study

How the trial runs.

The CD123-CAR T-cell therapy is a new treatment that is being investigated for treatment of AML/myelodysplastic syndrome (MDS), T- or B- acute lymphoblastic leukemia (ALL) or blastic plasmacytoid dendritic cell neoplasia (BPDCN). The purpose of this study is to find the maximum (highest) dose of CD123-CAR T cells that is safe to give to these patients.

This would include studying the side effects of the chemotherapy, as well as the CD123-CAR T-cell product on the recipient's body, disease and overall survival.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Inclusion Criteria for Procurement and T-cell Production:
  • Relapsed/refractory CD123+ disease defined as follows:
  • Relapsed disease: Patients developing recurrent disease after a first complete remission (CR)
  • Refractory disease: Patients not achieving a CR after 2 cycles of induction chemotherapy
  • Relapsed disease that is CD123 positive and CD19 negative/dim or patients otherwise ineligible for CD19 directed therapies including
  • Patients in 2nd or greater relapse

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.